US 11090293
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
granted A61KA61K31/437A61P
Quick answer
US patent 11090293 (Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering) held by OVID THERAPEUTICS INC. expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- OVID THERAPEUTICS INC.
- Grant date
- Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/437, A61P, A61P25/14